A detailed history of Systematic Financial Management LP transactions in Exelixis, Inc. stock. As of the latest transaction made, Systematic Financial Management LP holds 1,168,391 shares of EXEL stock, worth $38.9 Million. This represents 0.8% of its overall portfolio holdings.

Number of Shares
1,168,391
Previous 1,090,792 7.11%
Holding current value
$38.9 Million
Previous $24.5 Million 23.7%
% of portfolio
0.8%
Previous 0.77%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $1.7 Million - $2.14 Million
77,599 Added 7.11%
1,168,391 $30.3 Million
Q2 2024

Aug 15, 2024

SELL
$20.34 - $23.73 $823,139 - $960,329
-40,469 Reduced 3.58%
1,090,792 $24.5 Million
Q1 2024

May 14, 2024

SELL
$20.17 - $23.93 $81,688 - $96,916
-4,050 Reduced 0.36%
1,131,261 $26.8 Million
Q4 2023

Feb 14, 2024

SELL
$19.25 - $24.13 $701,412 - $879,224
-36,437 Reduced 3.11%
1,135,311 $27.2 Million
Q2 2023

Aug 14, 2023

SELL
$18.17 - $20.48 $798,698 - $900,239
-43,957 Reduced 3.62%
1,171,748 $22.4 Million
Q1 2023

May 12, 2023

BUY
$16.3 - $19.41 $73,659 - $87,713
4,519 Added 0.37%
1,215,705 $23.6 Million
Q4 2022

Feb 15, 2023

BUY
$14.96 - $17.39 $436,637 - $507,561
29,187 Added 2.47%
1,211,186 $19.4 Million
Q3 2022

Nov 14, 2022

SELL
$15.68 - $22.27 $108,160 - $153,618
-6,898 Reduced 0.58%
1,181,999 $18.5 Million
Q2 2022

Aug 15, 2022

BUY
$17.44 - $23.16 $628,084 - $834,084
36,014 Added 3.12%
1,188,897 $24.8 Million
Q1 2022

May 11, 2022

BUY
$17.03 - $22.67 $1.01 Million - $1.34 Million
59,087 Added 5.4%
1,152,883 $26.1 Million
Q4 2021

Feb 14, 2022

SELL
$15.84 - $21.88 $362,039 - $500,089
-22,856 Reduced 2.05%
1,093,796 $20 Million
Q3 2021

Nov 12, 2021

BUY
$16.3 - $21.14 $1.18 Million - $1.53 Million
72,326 Added 6.93%
1,116,652 $23.6 Million
Q2 2021

Aug 12, 2021

BUY
$17.95 - $25.56 $4.21 Million - $5.99 Million
234,467 Added 28.95%
1,044,326 $19 Million
Q1 2021

May 10, 2021

BUY
$20.53 - $25.22 $3.25 Million - $3.99 Million
158,392 Added 24.31%
809,859 $18.3 Million
Q4 2020

Feb 12, 2021

BUY
$18.39 - $24.8 $3.26 Million - $4.4 Million
177,383 Added 37.42%
651,467 $13.1 Million
Q3 2020

Nov 12, 2020

BUY
$20.67 - $26.94 $1.7 Million - $2.21 Million
82,043 Added 20.93%
474,084 $11.6 Million
Q2 2020

Aug 13, 2020

BUY
$16.46 - $27.42 $6.45 Million - $10.7 Million
392,041 New
392,041 $9.31 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Systematic Financial Management LP Portfolio

Follow Systematic Financial Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Systematic Financial Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Systematic Financial Management LP with notifications on news.